Segall Bryant & Hamill LLC Sells 16,468 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Segall Bryant & Hamill LLC reduced its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 42.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,515 shares of the specialty pharmaceutical company's stock after selling 16,468 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.07% of Collegium Pharmaceutical worth $672,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Invesco Ltd. boosted its position in shares of Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after acquiring an additional 289,335 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Collegium Pharmaceutical by 319.4% during the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock worth $8,341,000 after purchasing an additional 221,903 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth $3,489,000. Massachusetts Financial Services Co. MA increased its stake in shares of Collegium Pharmaceutical by 18.1% in the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company's stock worth $21,309,000 after buying an additional 109,655 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at $2,432,000.

Insider Activity at Collegium Pharmaceutical

In related news, Director John Gordon Freund sold 6,601 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $30.62, for a total value of $202,122.62. Following the transaction, the director owned 70,658 shares in the company, valued at $2,163,547.96. This trade represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.51% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on COLL shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Piper Sandler reiterated a "neutral" rating and issued a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Finally, Wall Street Zen cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 5th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $43.75.

Collegium Pharmaceutical Stock Performance

Shares of COLL traded up $0.77 during mid-day trading on Wednesday, hitting $32.41. The company's stock had a trading volume of 194,620 shares, compared to its average volume of 396,372. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $42.29. The company has a debt-to-equity ratio of 3.30, a quick ratio of 1.01 and a current ratio of 1.08. The firm has a market capitalization of $1.04 billion, a PE ratio of 26.57 and a beta of 0.64. The stock's 50-day moving average is $30.27 and its two-hundred day moving average is $29.76.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The business's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.45 earnings per share. As a group, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical announced that its board has approved a share buyback program on Monday, July 7th that allows the company to buyback $150.00 million in outstanding shares. This buyback authorization allows the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's board of directors believes its stock is undervalued.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.